MapLight Therapeutics, Inc.

NASDAQ:MPLT

Biotechnology

Healthcare
$6.65 +3.11%

+$0.39 today

Market cap
$283.41M
Beta
2.65
P/E (TTM)
-2.8
EPS (TTM)
-$4.41
52W Low $9.10High $40.43

Volume 0.42M

Average 0.73M

MPLT Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

MapLight Therapeutics, Inc.NASDAQ: MPLT

Effect of Forex Changes · Q1 FY2026 · quarter ended Mar 2026

Effect of forex changes outflow shrinks to $0

Q1 FY2026 effect of forex changes was $0, compared with $38.25M a year earlier. Trailing-twelve-month effect of forex changes was $0.

Context

  • Effect of forex changes increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly effect of forex changes holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$0+100.0% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Effect of Forex Changes vs competitors

How MPLT compares with its peers on the latest reported figures

  • MPLT's LTM Mar 2026 effect of forex changes of $0 is the 7th largest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of +100.0% is the 5th highest of 6, against a peer median of +3883.4%.
MPLT Competitors Peer median
Effect of Forex Changes for MPLT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$3.87M +55128.2%-71.7%—
GHRSGH Research PLCLTM Mar 2026$2.91M +3883.4%+264.2%—
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$633K +398.4%-48.4%0.5%
OVIDOvid Therapeutics Inc.LTM Mar 2026$289K +28800.0%—4.1%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$264K ———
ANROAlto Neuroscience, Inc.LTM Mar 2026$24K -14.3%+7.7%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$0 +100.0%——
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$0 ——0.0%
NERVMinerva Neurosciences, Inc.LTM Jun 2026$0 ———
AVXLAnavex Life Sciences Corp.LTM Dec 2025$0 ———
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding MPLT) $0+3883.4%-20.3%0.5%

Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.02M)(55.71M)(77.58M)(161.15M)
Depreciation & Amortization574K556K701K578K
Deferred Income Tax0000
Stock-Based Compensation0000
Change in Working Capital1.72M2.04M(3.07M)(12.84M)
Accounts Receivables0000
Inventory0000
Accounts Payables0000
Other Working Capital1.72M2.04M(3.07M)(12.84M)
Other Non-Cash Items1.14M1.11M1.13M35.27M
Operating Cash Flow(26.58M)(52.01M)(78.82M)(138.14M)
Capital Expenditures(746K)(462K)(770K)(473K)
Acquisitions (Net)0000
Purchases of Investments00(125.02M)(408.23M)
Sales of Investments0045M85.5M
Other Investing Activities0000
Investing Cash Flow(746K)(462K)(80.79M)(323.21M)
Debt Repayment0000
Common Stock Issued33.17M104.57M120.25M474.84M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities33.18M104.57M(2.19M)(5.02M)
Financing Cash Flow33.17M104.57M118.06M469.82M
Effect of Forex Changes21.81M027K0
Net Change in Cash27.67M52.1M(41.52M)8.48M
Free Cash Flow(27.32M)(52.47M)(79.59M)(138.61M)

MapLight Therapeutics, Inc.

NASDAQ:MPLT

Intrinsic Alpha fair value

Locked

Current Price

$6.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.